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Both the incidence of invasive fungal infections and rates of multidrug resistance
associated with fungal pathogen Candida glabrata have increased in recent years.
In this perspective, we will discuss the mechanisms underlying the capacity of
C. glabrata to rapidly develop resistance to multiple drug classes, including triazoles
and echinocandins. We will focus on the extensive genetic diversity among clinical
isolates of C. glabrata, which likely enables this yeast to survive multiple stressors,
such as immune pressure and antifungal exposure. In particular, over half of C. glabrata
clinical strains collected from U.S. and non-U.S. sites have mutations in the DNA
mismatch repair geneMSH2, leading to a mutator phenotype and increased frequencies
of drug-resistant mutants in vitro. Furthermore, recent studies and data presented here
document extensive chromosomal rearrangements among C. glabrata strains, resulting
in a large number of distinct karyotypes within a single species. By analyzing clonal,
serial isolates derived from individual patients treated with antifungal drugs, we were
able to document chromosomal changes occurring in C. glabrata in vivo during the
course of antifungal treatment. Interestingly, we also show that both MSH2 genotypes
and chromosomal patterns cluster consistently into specific strain types, indicating that
C. glabrata has a complex population structure where genomic variants arise, perhaps
during the process of adaptation to environmental changes, and persist over time.
Keywords: antifungal resistance, Candida glabrata, DNA repair, MSH2, echinocandins, triazoles, karyotyping,
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EPIDEMIOLOGY OF FUNGAL INFECTIONS AND TREATMENT
OPTIONS
Fungi infect billions of people around the world each year. Although most fungal infections remain
superficial, millions develop invasive mycoses, which have alarmingly high mortality rates ranging
from 30 to 90%, even with antifungal treatment (Pfaller and Diekema, 2007; Nivoix et al., 2008;
Wingard et al., 2008; Roilides et al., 2009). According to the CDC and WHO, the number of
deaths caused by fungal infections is comparable to the numbers attributed to the world’s deadliest
diseases, including malaria and tuberculosis. The majority of invasive fungal infections (IFIs)
and deaths occur in immunocompromised individuals and are caused by species of Candida,
Aspergillus, or Cryptococcus (Pfaller and Diekema, 2007). While Aspergillus and Cryptococcus
are acquired from the environment, Candida is a human commensal and most infections arise
endogenously. Candida species account for most mucosal and invasive fungal infections worldwide
(Pfaller et al., 2006) and are associated with significant healthcare costs (Zaoutis et al., 2005; Pfaller
and Diekema, 2010). Approximately 50% of candidemia cases in the U.S. are caused by C. albicans
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(Hajjeh et al., 2004; Azie et al., 2012). However, over the past 20
years there has been a shift toward non-albicans Candida species
(Pfaller and Diekema, 2004; Diekema et al., 2012; Lockhart et al.,
2012), and the identity of leading non-albicans species causing
disease varies upon geographical location. In the U.S., C. glabrata
accounts for ∼25% of infections, followed by C. parapsilosis
(∼15%) and C. tropicalis (∼10%) (Pfaller et al., 2011a,b; Azie
et al., 2012; Lockhart et al., 2012). Decreases in C. albicans
infections have been complemented by increases in C. glabrata
infections in most U.S. cities (Lockhart et al., 2012). The reason
for the steep increase in reported C. glabrata infections is not
known, although advances in diagnostic methods, increases in
the elderly population, geography, and widespread fluconazole
use (see below) have been proposed to play roles (Pfaller et al.,
2006, 2009; Diekema et al., 2012).
Patients undergoing procedures such as stem cell or organ
transplantation, surgery, or cancer treatment are at high
risk for developing life-threatening IFIs. Consequently, such
patients are commonly placed on antifungal prophylaxis with
either triazole or echinocandin drugs. The triazole class of
antifungal drugs targets the biosynthesis of ergosterol, which
is a critical component of fungal cell membranes, while the
echinocandins block the biosynthesis of beta-1,3-glucan, a
fundamental structural component of the cell wall. Both drug
classes are recommended first-line therapy for a variety of IFIs
caused by Candida species (Pappas et al., 2016). A consequence
of the widespread use of triazole antifungals (e.g., fluconazole)
for prophylaxis or therapy is the selection of Candida species
that readily develop resistance, such as C. glabrata (Lortholary
et al., 2011). Approximately 20–30% of C. glabrata strains,
but less than 5% of C. albicans strains, exhibit fluconazole
resistance in the U.S. (Castanheira et al., 2014). C. glabrata
readily develops cross-resistance to azoles, including fluconazole,
itraconazole, voriconazole and posaconazole, which is often
associated with upregulation of ATP-binding cassette (ABC)
transporters, such as CDR1 and SNQ2, that effectively pump
the drugs out of the yeast cell (Sanglard et al., 1999, 2001;
Izumikawa et al., 2003; Torelli et al., 2008). Upregulation of
these drug eﬄux pumps is usually accompanied by a gain-of-
function mutation in the transcription factor PDR1 (Vermitsky
and Edlind, 2004; Tsai et al., 2006; Vermitsky et al., 2006),
prompting the recent development of a novel inhibitor that
interferes with Pdr1 binding to the Mediator complex preventing
transcription initiation (Nishikawa et al., 2016). Specific pdr1
mutations in C. glabrata can also lead to a gain of fitness
through enhanced adhesion and virulence (Ferrari et al., 2011;
Vale-Silva et al., 2013, 2016). Additional mechanisms of triazole
resistance, such as mutation of the drug target (ERG11; ergosterol
biosynthesis) or mutation of genes (e.g., ERG3) that prevent the
production of toxic intermediates caused by triazole action, have
been identified in other Candida species (Cowen et al., 2014), yet
rarely in C. glabrata (Hull et al., 2012).
In some settings, such as those involving hematologic
malignancies, C. glabrata is isolated more often than C.
albicans, making it the leading cause of IFIs (Hachem et al.,
2008). Therefore, current treatment recommendations advise
administration of an echinocandin to patients with known C.
glabrata infections (Pappas et al., 2016). While the mechanism
of echinocandin resistance is consistent across Candida species,
the rates of resistance have increased the greatest (from 3
to 12%) in C. glabrata (Alexander et al., 2013) for reasons
that are still largely unclear. Echinocandin resistance develops
upon mutation of the catalytic subunits (Fks1/Fks2) that make
up the echinocandin target enzyme, beta-1,3-glucan synthase.
Mutations are generally found in the “hot spot” regions of either
FKS gene and result in cross-resistance to all echinocandins
(caspofungin, micafungin, and anidulafungin) (Perlin, 2015).
Triazole-resistant clinical isolates (Pfaller et al., 2005; Messer
et al., 2006) and laboratory strains (Niimi et al., 2006) that
demonstrate increased drug eﬄux pump expression remain
susceptible to the echinocandins in laboratory liquid assays. One
study from 2003 (Schuetzer-Muehlbauer et al., 2003) did report
reduced caspofungin susceptibility upon overexpression of the
ABC eﬄux pump CDR2 in C. albicans, although this occurred
under specific testing conditions and the other echinocandins
(anidulafungin andmicafungin) were not yet available for testing.
Overall, the echinocandins do not appear to be substrates for
drug eﬄux pumps conferring azole resistance. Echinocandins are
also effective against some Candida biofilms, which are normally
refractory to triazole treatment (Kuhn et al., 2002; Katragkou
et al., 2008). A third class of antifungals, the polyenes, directly
targets ergosterol in the cell membrane disrupting cellular
permeability; however, treatment of invasive Candida infections
with the polyene amphotericin B is only recommended as a
second-line agent due to toxicity issues (Pappas et al., 2016).
THE ADAPTIVE RESPONSE
One factor that can influence the survival or persistence of fungi
between the initial drug exposure and acquisition of resistance-
conferring mutations is the adaptive response. Upon exposure to
environmental stresses, such as temperature, ionic, oxidative, and
osmolarity changes, and/or drug pressure, fungi activate stress
responses to mitigate the harmful effects and avoid death. Of
particular importance upon echinocandin exposure is the cell
wall integrity (CWI) pathway, which regulates glucan synthesis
through Rho1 and cell wall repair (Levin, 2005). Following
cell wall stress, Rho1 activation leads to activation of protein
kinase C (PKC1) and upregulation of the FKS genes. Targeting
the CWI pathway through deletion of PKC1 or activated MAP
kinases (e.g., CgSLT2) induces echinocandin hypersensitivity;
while conversely, an increased activation of the pathway, such
as through over-expression of CgSLT2, reduces susceptibility
(increases tolerance) of C. glabrata to echinocandins (Cota
et al., 2008; Miyazaki et al., 2010a; Schwarzmuller et al., 2014).
Induction of the CWI pathway in Candida species (Stevens et al.,
2006; Walker et al., 2013), including C. glabrata (Cota et al.,
2008), has been linked to increased production of other cell wall
components, such as chitin, potentially compensating for the loss
of beta-1,3-glucans. Genetic (Ueno et al., 2011; Schwarzmuller
et al., 2014) or chemical (Miyazaki et al., 2010a) targeting of chitin
synthase has been shown to increase C. glabrata susceptibility to
echinocandins in vitro. Regulators of the CWI pathway, such as
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Hsp90 and calcineurin, can similarly influence the susceptibility
of C. glabrata to echinocandin and triazole drugs (Singh et al.,
2009; Miyazaki et al., 2010b). Other epigenetic mechanisms,
such as chromatin modification, may impact drug activity; for
example, histone deacetylase inhibitors act synergistically with
antifungals (Garnaud et al., 2016). In addition to genetic and
epigenetic changes, alterations in chromosomal structure may
also influence survival in vivo and antifungal susceptibility;
this will be discussed in greater depth in subsequent sections
of this perspective. Tolerance mechanisms may “prime” cells,
particularly C. glabrata, to better survive adverse conditions
in vivo and, in turn, better equip fungi to survive antifungal
pressure. Inversely, abrogating the adaptive response of C.
glabrata may increase the killing (fungicidal index) efficacy of
antifungals. Thus, a better understanding of how fungi control
these adaptive mechanisms, particularity in vivo, and how fitness
may be affected is warranted.
In addition to individual cell responses to drugs, which are
determined largely by cell genotype, population responses may
also play a role in drug tolerance. Although acquisition of a
pdr1 mutation is required for stable triazole resistance, studies
have demonstrated the ability of C. glabrata subpopulations
originating from a clonal population to develop heteroresistance
to fluconazole through transient upregulation of eﬄux pumps
(Claudino et al., 2009; Ben-Ami et al., 2016). Development of
tolerance to fluconazole treatment at the population level may
be one consequence of heteroresistance, which in turn, may
allow the yeast to adapt and “buy time” until beneficial, stable
mutations develop. As stated earlier, specific pdr1 mutations can
also enhance the fitness of C. glabrata and increase virulence
through adhesion upregulation (Vale-Silva et al., 2016). C.
glabrata heteroresistance was not observed in response to the
echinocandins, which may reflect its fungicidal mechanism of
action (at least in vitro) (Ben-Ami et al., 2016) or potential
associated fitness costs. However, yeast are exposed to additional
pressures in vivo that may induce some kind of transient
heterotolerance to the echinocandins that is not necessarily
measurable in vitro.
THE EMERGENCE OF MULTIDRUG
RESISTANCE IN C. GLABRATA
While the individual mechanisms of C. glabrata triazole and
echinocandin resistance have been extensively examined, the
sudden emergence of strains that are resistant to both drug classes
is surprising and alarming. Resistance to multiple antifungal
classes, or multidrug resistance (MDR), has been reported most
frequently in this fungus (Pfaller et al., 2012). A CDC/SENTRY
Antimicrobial Surveillance Program study found that while none
of the fluconazole-resistant C. glabrata isolates from 2001 to
2004 demonstrated echinocandin resistance, 11% of fluconazole-
resistant isolates from 2006 to 2010 were also resistant to an
echinocandin (Pfaller et al., 2012). Another study, performed at
Duke Hospital in 2010, found that 14% of fluconazole-resistant
isolates also exhibited resistance to at least one echinocandin
and that 3.5% of all C. glabrata isolates were MDR (Alexander
et al., 2013). Additionally, a survey ofC. glabrata isolates obtained
from a cancer hospital between 2005 and 2013 reported nearly
7% as MDR (Farmakiotis et al., 2014). As a consequence of
current guidelines for prophylaxis and treatment, the majority of
MDR C. glabrata strains have acquired resistance to triazole and
echinocandin class antifungals, with rare isolates demonstrating
resistance to amphotericin B (Farmakiotis et al., 2014; Cho
et al., 2015). Collectively, the emergence of MDR in C. glabrata,
although still uncommon, is a cause for grave concern given
the fact that echinocandin and triazole use has increased
significantly over the past 10 years (Pfaller et al., 2012), and
the echinocandins are currently the preferred treatment for
C. glabrata invasive infections. A better understanding of the
mechanisms responsible for the emergence or perpetuation of
MDR will help assess factors that can both prevent and overcome
resistance.
Many groups, including ours, have attributed the observed
increases in drug resistance rates to the haploid genome of C.
glabrata. While this is most likely a factor, our recent studies have
suggested that other prominent biological factors may contribute
more profoundly to resistance emergence. Here, we discuss
genetic mechanisms, both at the chromosomal and nucleotide
levels, which can increase the mutability and/or genetic diversity
of C. glabrata. We propose that these mechanisms allow strains
of C. glabrata to create genetically diverse populations within
the human host and improve the yeast’s chances of surviving
multiple stressors, including antifungal treatment. We show that
nucleotide polymorphisms and chromosomal rearrangements
vary widely in C. glabrata yet group reliably into strain types.
In this perspective, we will both summarize previously published
studies and present new data that support these claims.
GENETIC DIVERSITY AND THE MUTATOR
PHENOTYPE
All cells contain multiple mechanisms dedicated to repairing
DNA damage that can result from either exogenous (e.g.,
chemicals or radiation) or endogenous (e.g., reactive oxygen
radicals or DNA polymerase errors) sources. In eukaryotes
these mechanisms include DNA-damage checkpoints and several
highly conserved DNA repair systems, including double-strand
break repair (DSBR), base-excision repair (BER), nucleotide-
excision repair (NER), and mismatch repair (MMR). Defects in
these mechanisms are often associated with increased mutation
rates or genome rearrangements, and in humans they are
associated with a predisposition to specific cancers (Hakem,
2008). Thus, defects in DNA repair may also underlie the
emergence of drug-resistant variants in fungal pathogens such
as C. glabrata. DNA repair has been extensively studied in the
model organism Saccharomyces cerevisiae. Yet, its role in fungal
pathogens, especially in connection to emergence of antifungal
resistance, has only begun to be addressed.
One study investigated the involvement of DNA repair
mechanisms in drug resistance in C. albicans and demonstrated
that mutants of MMR and DSBR, but not BER or NER, lead to
increased appearance of fluconazole-resistant colonies (Legrand
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et al., 2007, 2008). Recently, we examined the role of DNA
repair in C. glabrata (Healey et al., 2016). We discovered that
over half (55%) of all C. glabrata isolates (susceptible and
resistant) recovered from patients contain mutations within the
MMR gene MSH2. Strains with specific msh2 mutations exhibit
a higher frequency of emergence of resistance in vitro, and
deletion of MSH2 causes elevated propensity to breakthrough
antifungal treatment in a mouse model of gastrointestinal (GI)
colonization. Furthermore, analysis of serial clinical isolates
demonstrated that msh2 mutations pre-date the emergence of
antifungal resistance. Interestingly, MSH2 genotypes appear to
be geographically dependent. The overwhelming majority of
strains (75 of 76) that exhibit msh2-E231G/L269F or msh2-
P208S/N890I were recovered at U.S. based medical centers.
Strains containing either msh2-V239L/A942T or msh2-V239L
were identified in both U.S. and non-U.S. (Switzerland, Qatar,
and India) centers, although these genotypes were predominant
(95 of 125) among the msh2 mutant alleles identified from the
non-U.S. centers. These geographical differences are most likely
a result of population and/or treatment differences (see “Strain
type” section below). Our study suggests that msh2mutation is a
driver of the acquisition of antifungal resistance in C. glabrata.
Whether other fungi exhibit similar mechanisms of genetic
diversity through MMR remains to be addressed.
Through in vivo competition assays utilizing both GI
colonization and bloodstream infection mouse models, we have
demonstrated that complete loss of MMR function (msh2∆)
impacts fitness of C. glabrata in the host (Healey et al., 2016).
However, strains exhibiting one of the aforementioned msh2
mutations lead to only partial loss-of-function (data not shown)
and may not suffer from the extremely high mutation rate and
fitness defect observed with msh2∆. Additional mechanisms of
DNA repair, including other MMR genes, and other cellular
systems responsible for genome integrity maintenance, such as
DNA-damage checkpoints, may also influence the mutagenic
potential of C. glabrata clinical strains.
GENETIC DIVERSITY OF CHROMOSOME
STRUCTURE
Normally, all chromosomes in a cell are present at the same
copy number; however, deviations from this norm, aka aneuploid
isolates, have been reported in fungal pathogens (Bennett, 2010;
Gerstein et al., 2015). A number of studies have suggested that
variations in chromosome organization and copy number can
be advantageous to fungal cells under certain conditions and
may provide a route for rapid adaptation to stress, such as
the host immune response or antifungal drugs. In C. albicans,
chromosomal rearrangements (copy number variation, loss of
heterozygosity, translocations, chromosome truncations) occur
in response to stresses such as heat shock, host-pathogen
interactions, and the presence of antifungal drugs (Selmecki
et al., 2006; Bouchonville et al., 2009; Forche et al., 2009). As
a result, the karyotypes (the number and size of chromosomes)
between different isolates may vary drastically (Merz et al.,
1988; Rustchenko-Bulgac, 1991; Pfaller et al., 1994). Even greater
karyotypic variability has been observed in clinical isolates of
C. glabrata. Karyotyping using pulsed-field gel electrophoresis
(PFGE), which separates whole chromosomes, revealed that
C. glabrata genome organization varies significantly among
different isolates (Muller et al., 2009; Polakova et al., 2009).
Similar to what has been described in C. albicans, the most
frequent genome rearrangements identified were translocations
of chromosomal arms and inter-chromosomal duplications, but
formation of novel chromosomes was also reported (Muller et al.,
2009; Polakova et al., 2009).
Since genome plasticity has been connected with antifungal
drug resistance in C. glabrata (Shin et al., 2007; Polakova
et al., 2009), we analyzed the karyotypes of serial clinical C.
glabrata isolates from our laboratory’s strain collection. All strains
were subjected to multi-locus sequence typing (MLST) analysis
(Dodgson et al., 2003) to verify that each pair originated from
the same lineage; indeed, both strains from each pair were of
the same strain type (Figure 1A). MICs to fluconazole and the
echinocandins were determined by the CLSI broth microdilution
method (CLSI, 2012) and FKS1, FKS2, PDR1, and MSH2 genes
were sequenced for all isolates (Figure 1A). In each case, a
bloodstream isolate was obtained before and after echinocandin
therapy, and in each case the first isolate was echinocandin
sensitive, while the second isolate had acquired echinocandin
resistance and an fks mutation. One set of isolates exhibited
resistance to fluconazole and contained a pdr1 mutation. To
determine whether these changes were also accompanied by
large-scale chromosomal rearrangements, we performed PFGE.
Karyotypes of the six isolates presented unique chromosomal
profiles (Figure 1B). While strains isolated from the same patient
were more similar to each other than strains isolated from
different patients, even sequential isolates obtained from the
same individual had distinct chromosomal bands, particularly
among the larger chromosomes (Figure 1B). Thus, changes
in chromosomal architecture occurred during microevolution
of C. glabrata within the host, possibly in response to
echinocandin treatment. Thus, genome rearrangements may be
one mechanism used by C. glabrata to diversify the phenotypic
properties of the population and promote adaptation under
specific stress conditions.
C. GLABRATA POPULATION STRUCTURE:
STRAIN TYPES ARE CHARACTERIZED BY
SPECIFIC NUCLEOTIDE
POLYMORPHISMS AND GENOME
REARRANGEMENTS
As described above, C. glabrata clinical isolates have highly
variable chromosomal profiles. It has been reported that
this fungus also shows genetic variability at the level of
genomic nucleotide sequence (Lin et al., 2007). A MLST
scheme based on six different loci has thus far identified
over 80 different C. glabrata sequence types (STs, or clades)
(Dodgson et al., 2003) and our preliminary analysis indicates
that this number is likely much higher. For instance, MLST
typing of 48 clinical strains identified 6 strains containing
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FIGURE 1 | Electrophoretic karyotypes of three pairs of serial C. glabrata clinical isolates. (A) The minimum inhibitory concentrations (MIC), sequence type
(ST), and genome mutations of two bloodstream isolates (A and B) from three individual patients (1, 2, and 3) are shown. (B) Karyotypes of the same isolates obtained
with PFGE analysis. The karyotype of the C. glabrata reference strain CBS138/ATCC2001 is also shown. M: CHEF DNA chromosomal size marker (S. cerevisiae strain
YNN295) (BIO-RAD). ANF, anidulafungin; MCF, micafungin; CSF, caspofungin; FLZ, fluconazole. *Gain of function mutations.
novel MLST alleles or novel configurations of previously
reported alleles (data not shown). We also found that different
msh2 alleles (see above and Figure 1A) are characteristic of
distinct STs/clades, indicating that different STs may have
different propensity toward mutability and acquiring drug
resistant gene variants. This conclusion is significant because
the distribution of C. glabrata STs varies both by geography
and over time (Dodgson et al., 2003; Lott et al., 2010). For
instance, Figure 2A shows that C. glabrata ST distribution
in Atlanta area hospitals changed significantly between 1992
and 2008, the time period that includes the introduction of
echinocandins (Lott et al., 2010). One noteworthy change
is the increased prevalence of ST16, which carries an msh2
mutation and may therefore acquire drug resistance at elevated
rates.
The observation that different C. glabrata STs carry different
msh2 alleles makes it highly likely that other important
determinants of drug resistance or virulence also vary among
STs. A straightforward way to identify such determinants is
by genome sequencing. However, the great degree of genomic
rearrangement among strains presents a barrier to typical
shotgun sequencing approaches that use a reference strain as
template. Indeed, while the genome of a reference C. glabrata
laboratory strain (CBS138) has been sequenced, we were not able
to use that strain’s genomic sequence as a template for assembling
the sequences of other strains, e.g., various clinical isolates, due
to the high karyotypic variability among strains (Muller et al.,
2009; Polakova et al., 2009; Bader et al., 2012; Figure 1B). Thus,
it will be necessary to assemble the genomes of individual clinical
C. glabrata isolates de novo using techniques such as optical
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FIGURE 2 | Temporal changes and chromosomal patterns associated
with C. glabrata strain type. (A) The population structure of C. glabrata
isolates obtained from candidemia patients in Atlanta hospitals during the
indicated years. Each circle represents a particular ST and the msh2 profile of
each ST is indicated by color (adapted from Lott et al., 2010). (B) Strains
belonging to the same ST have similar chromosome patterns as determined
by pulse field gel electrophoresis (PFGE). Chromosome configurations for
strains of five different STs are shown and the origins of every clinical isolate
are indicated below. Laboratory strains (BG2 and ATCC) or isolates recovered
from individual patients at six separate U.S. medical centers (US1-6) or a
medical center in Qatar were analyzed.
restriction mapping and long read DNA sequencing (Neely et al.,
2011; Rhoads and Au, 2015).
We also examined the chromosomal architecture of strains
belonging to different STs. Because it was originally proposed
that chromosomal rearrangements in C. glabrata arise as part
of the virulence process or adaptation to drug pressure and
emergence of resistance (Polakova et al., 2009), we expected
that there would be no correspondence between ST identity
and chromosomal configuration. However, we were surprised
to discover similarities in chromosomal architecture among
strains belonging to the same STs (Figure 2B). Together with
data presented above (Figure 1B), this observation suggests that
chromosomal variants of C. glabrata both exist as commensal
populations, where different STs are characterized by specific
chromosomal configurations, and arise de novo, perhaps in
response to pressure from the host and antifungal drug
treatment.
CONCLUSION
Accumulating evidence suggests that both increasing numbers
of immunocompromised patients and the widespread use of
triazoles, particularly fluconazole, have facilitated an increased
prevalence of C. glabrata infections and more alarmingly,
the emergence of multidrug resistant strains. Here we have
summarized the current understanding of factors driving
drug resistance in C. glabrata. Maximizing genetic diversity,
a hallmark of C. glabrata, is most apparent by the high
prevalence in the global population of mutator phenotypes
mediated by mutations in MSH2. Additionally, new data
is presented supporting the concept that C. glabrata has a
surprisingly plastic and mutable genome. It appears that, in
contrast to many organisms, C. glabrata can tolerate such a
high degree of genome rearrangement and thrive under these
circumstances, perhaps through acquisition of gain-of-fitness
mutations. Continued tracking of C. glabrata strain types in
medical centers around the globe will aid in the understanding of
C. glabrata population structure and how pathogenesis and drug
resistance are associated with different strains of C. glabrata.
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